Preventing rabies with the Verorab vaccine: 1985-2005 Twenty years of clinical experience
- PMID: 17983973
- DOI: 10.1016/j.tmaid.2007.07.004
Preventing rabies with the Verorab vaccine: 1985-2005 Twenty years of clinical experience
Abstract
Purified rabies vaccine cultured on Vero cells (Verorab, sanofi pasteur) is WHO-approved for pre- and post-exposure prophylaxis by intradermal and intramuscular routes. During 20 years of use, over 40 million doses of Verorab have been administered in more than 100 countries. No serious adverse event due to Verorab has been reported in clinical trials involving 3937 persons, and Verorab is better tolerated than human diploid cell vaccine (HDCV). Pre-exposure prophylaxis is confirmed immunogenic in 1437 subjects by all routes, with prompt responses following boosting; Verorab boosts effectively subjects pre-immunized with HDCV. Unlike HDCV, Verorab is not associated with post-boosting serum sickness. In the absence of data in immunodeficient/HIV-positive individuals, pre-exposure immunization is urged as early as possible. Essen, Zagreb, Thai Red Cross Intradermal (TRC-ID) and other post-exposure intramuscular and intradermal regimens are documented. Two thousand one hundred and eighty-three subjects received post-exposure prophylaxis, including 874 high risk, severe or confirmed rabid attacks. Co-administration of rabies immune globulin (RIG) does not affect neutralizing antibody levels when Essen or TRC-ID regimens are employed; levels are lower with the Zagreb regimen. Verorab has been administered safely and effectively post-exposure to 251 pregnant women, without any increase in congenital malformations or spontaneous abortions. From a pediatric perspective, safety and efficacy have been demonstrated in 759 children (0-15 years). Intradermal post-exposure Verorab is an effective and inexpensive option for developing countries. Inadvertent subcutaneous administration does not reduce immunogenicity. WHO already strongly recommends the replacement of nerve tissue vaccines with modern vaccines. Extensive clinical experience supports the use of Verorab for intramuscular and intradermal pre- and post-exposure prophylaxis, including in special situations.
Similar articles
-
Rabies post-exposure prophylaxis vaccination with purified chick embryo cell vaccine (PCECV) and purified Vero cell rabies vaccine (PVRV) in a four-site intradermal schedule (4-0-2-0-1-1): an immunogenic, cost-effective and practical regimen.Vaccine. 2006 May 8;24(19):4116-21. doi: 10.1016/j.vaccine.2006.02.036. Epub 2006 Feb 28. Vaccine. 2006. PMID: 16545510 Clinical Trial.
-
A comparative study on the safety and immunogenicity of Purified duck embryo vaccine [corrected] (PDEV, Vaxirab) with purified chick embryo cell vaccine (PCEC, Rabipur) and purifed vero cell rabies vaccine (PVRV, Verorab).Vaccine. 2009 Dec 10;28(1):148-51. doi: 10.1016/j.vaccine.2009.09.090. Epub 2009 Oct 8. Vaccine. 2009. PMID: 19818720 Clinical Trial.
-
A next-generation, serum-free, highly purified Vero cell rabies vaccine is safe and as immunogenic as the reference vaccine Verorab® when administered according to a post-exposure regimen in healthy children and adults in China.Vaccine. 2013 Dec 5;31(50):5940-7. doi: 10.1016/j.vaccine.2013.10.043. Epub 2013 Oct 19. Vaccine. 2013. PMID: 24148575 Clinical Trial.
-
30 Years of rabies vaccination with Rabipur: a summary of clinical data and global experience.Expert Rev Vaccines. 2015 Mar;14(3):351-67. doi: 10.1586/14760584.2015.1011134. Expert Rev Vaccines. 2015. PMID: 25683583 Review.
-
[Post-exposure antirabies prophylaxis in pregnant women].Ginecol Obstet Mex. 1994 Jan;62:13-6. Ginecol Obstet Mex. 1994. PMID: 8168717 Review. Spanish.
Cited by
-
Changes in the dynamic characteristics of G-protein can alter the immune-protection efficacy of rabies virus vaccine.J Virol. 2025 Mar 18;99(3):e0195424. doi: 10.1128/jvi.01954-24. Epub 2025 Feb 21. J Virol. 2025. PMID: 39982033 Free PMC article.
-
Immunogenicity and Safety of a Purified Vero Rabies Vaccine-Serum Free, Compared With 2 Licensed Vaccines, in a Simulated Rabies Post-Exposure Regimen in Healthy Adults in France: A Randomized, Controlled, Phase 3 Trial.Clin Infect Dis. 2024 Jun 14;78(6):1748-1756. doi: 10.1093/cid/ciae137. Clin Infect Dis. 2024. PMID: 38478634 Free PMC article. Clinical Trial.
-
Exposure to rabies during pregnancy.CMAJ. 2018 Oct 29;190(43):E1281-E1283. doi: 10.1503/cmaj.180727. CMAJ. 2018. PMID: 30373741 Free PMC article. No abstract available.
-
Human rabies in Côte d'Ivoire 2014-2016: Results following reinforcements to rabies surveillance.PLoS Negl Trop Dis. 2018 Sep 6;12(9):e0006649. doi: 10.1371/journal.pntd.0006649. eCollection 2018 Sep. PLoS Negl Trop Dis. 2018. PMID: 30188890 Free PMC article.
-
Improving systematic rabies surveillance in Cameroon: A pilot initiative and results for 2014-2016.PLoS Negl Trop Dis. 2018 Sep 6;12(9):e0006597. doi: 10.1371/journal.pntd.0006597. eCollection 2018 Sep. PLoS Negl Trop Dis. 2018. PMID: 30188891 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical